Retatrutide is a triple hormone receptor agonist under active research for its effects on metabolic function. Unlike dual agonists such as tirzepatide, retatrutide targets three receptors simultaneously: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This triple mechanism has generated significant interest among metabolic researchers.
Mechanism of Action
GLP-1 receptor activation slows gastric emptying and modulates appetite signaling centrally. GIP receptor activation enhances insulin secretion in a glucose-dependent manner. Glucagon receptor agonism increases energy expenditure — a mechanism largely absent from earlier GLP-1-only compounds. The combination of all three pathways produces additive effects on energy balance that researchers find distinct from single or dual agonists.
Research Findings
Phase 2 trial data published in the New England Journal of Medicine (2023) reported mean body weight reductions of 17.5% at 24 weeks in the highest dose cohort. This exceeded results seen with semaglutide at comparable timepoints in similar populations. Liver fat reduction was also significant, with MRI-measured hepatic fat fraction dropping substantially across dose groups.
Gastrointestinal Profile
Nausea, vomiting, and diarrhea are the most commonly reported adverse events in retatrutide research, consistent with the class. Events were predominantly mild to moderate and concentrated in the dose titration phase. Researchers using standardized titration schedules report better tolerability profiles than those using fixed dosing.
Research Applications
Retatrutide is being studied for metabolic syndrome, non-alcoholic steatohepatitis (NASH), obesity, and type 2 diabetes models. Its glucagon component makes it particularly relevant for hepatic lipid metabolism research where pure GLP-1 agonists show more limited effects.
Storage and Handling
Lyophilized retatrutide should be stored at -20C. After reconstitution with bacteriostatic water, the solution is stable for approximately 28 days refrigerated at 2-8C. Standard insulin syringe volumes apply for research dosing.
For in vitro research use only. Not for human or veterinary use, therapeutic, or diagnostic purposes.